A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) (NCT05321082)
FIBRONEER 23
This trial is No longer recruiting
Registration number NCT05321082
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Ian Glaspole
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR